Merck Silence On OTC Singulair Speaks Volumes On Switch Outlook
This article was originally published in The Pink Sheet Daily
Merck’s silence on an OTC version of Singulair is a sign of the relatively “quiet” 2015 switch market despite the call for novel switches, particularly to treat chronic conditions, from FDA’s Nonprescription Drug Safe Use Regulatory Expansion Initiative.
You may also be interested in...
Naloxone OTC Switch NDA Has US FDA Concerned Labeling Will Cause User Error, Delay Delivery
CDER will ask advisory panel “whether additional labeling information might mitigate risk of use errors” for Emergent’s naloxone nasal spray made available OTC and whether results of firm’s human factors study “support that consumers are able to correctly administer nonprescription [naloxone nasal spray] in an emergency situation.”
US FDA Beats Clock On NDAC Charter Renewal
Give agency credit for beating the expiration date after missing it in previous renewals.
Before Asking FDA For Novel OTC Switch, Be Sure DFL Alone 'Can't Get There'
"You need to demonstrate to the best of your ability that you can't get there with just the Drug Facts label," says ONDP Director Theresa Michele during presentation on the FDA office' work over the past year at Consumer Healthcare Products Association's annual regulations and science conference.